Next-generation sequencing is a prerequisite for personalized lung cancer treatment

Authors

  • O. I. Vynnychenko Sumy Regional Clinical Oncology Center 31, Pryvokzalna Str., Sumy, Ukraine, 40022 Author
  • R. A. Moskalenko Sumy State University 116, Kharkivska Str., Sumy, Ukraine, 40007 Author
  • D. S. Kozakov Medical Laboratory CSD 22B, Zhmerynskaia Str., Kyiv, Ukraine, 03148 Author
  • S. S. Livshun Medical Laboratory CSD 22B, Zhmerynskaia Str., Kyiv, Ukraine, 03148 Author
  • O. M. Sulaieva Medical Laboratory CSD 22B, Zhmerynskaia Str., Kyiv, Ukraine, 03148 Author

DOI:

https://doi.org/10.7124/bc.000ACA

Keywords:

non–small cell lung cancer, next–generation sequencing genetic disorders, EGFR, KRAS

Abstract

Aim. Non-small cell lung cancer (NSCLC) is characterized by a wide range of genetic abnormalities that impact the disease prognosis. However, the data on frequency of various genetic disorders in lung cancer in the Ukrainian population are limited. Our study aimed to evaluate the frequency of genetic alterations in NSCLC samples to identify potential candidates for personalized treatment. Conclusions. The high frequency and variety of genetic alterations in NSCLC determine the expediency of NGS testing to personalize the treatment of patients with NSCLC.
biopolym.cell-2024-40-3-cover.png

Downloads

Published

2024-09-10

Issue

Vol. 40 No. 3 (2024)

Section

Chronicle and Information